Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms

Oncotarget

Volumn 4, Issue 4, 2013, Pages 622-635

  Axelrod, Mark ^a   Gordon, Vicki L ^a   Conaway, Mark ^b   Tarcsafalvil, Adel ^a,c   Neitzkel, Daniel J ^a,d   Gioeli, Daniel ^a   Weber, Michael J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Compensatory signaling; Crosstalk; Feedback inhibition; Pathway interactions; Targeted therapies

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; AT 7867; BAICALEIN; BUTYRIC ACID; DOCEBENONE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; MKK 886; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NORDIHYDROGUAIARETIC ACID; PROTEIN BAD; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; S6 KINASE; SERINE; SHORT HAIRPIN RNA; THREONINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH THROUGHPUT SCREENING; HUMAN; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84879134966     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.938     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000 Jan;100(1):57-70.
2. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004 Jun;304(5676):1497 -1500.
3. Ellis LM, Hicklin DJ. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clinical Cancer Research 2009 Dec;15(24):7471-7478.
4. Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF, Conaway M, Weber MJ. Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics 2011 Jun;10(9):1581-1590.
5. Chandarlapaty S. Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer. Cancer Discovery 2012 Apr;2(4):311-319.
6. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer 2010;9(5):75.
7. Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncology 2012 Aug;8(8):999-1014.
8. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013 Jan;12(1):35-50.
9. Roller D, Axelrod M, Capaldo B, Jensen K, Mackey A, Weber MJ, Gioeli D. Synthetic lethal screening with small molecule inhibitors provides a pathway to rational combination therapies for melanoma. Molecular Cancer Therapeutics 2012 Sep;11(11):2505-2515.
10. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery 2013;3(1):52-67
11. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang D-Y, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells. Molecular Endocrinology 1997 Apr;11(4):450 -459.
12. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B, Coetzee GA. Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity. PLoS ONE 2008 Nov;3(11):e3645.
13. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. Androgen Receptor Expression in Androgen-independent Prostate Cancer Is Associated with Increased Expression of Androgen-regulated Genes. Cancer Research 1998 Dec;58(24):5718-5724.
14. Serra V, Scaltriti M, Prudkin L, Eichhorn PJA, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011 Jun;30(22):2547-2557.
15. Davies SP, Reddy H, Calvano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemical Journal 2000;(351):95-105.
16. Ramalingam SS, Parise RA, Ramananthan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies. Clinical Cancer Research 2007 Jun;13(12):3605-3610.
17. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. European Journal of Cancer and Clinical Oncology 1987 Sep;23(9):1283-1287.
18. Budworth J, Davies R, Malkhandi J, Gant T, Ferry D, Gescher A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer 1996 May;73(9):1063-1068.
19. Grimshaw KM, Hunter L-JK, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth. Molecular Cancer Therapeutics 2010 May;9(5):1100-1110.
20. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proceedings of the National Academy of Sciences 2001;98(17):9666 -9670.
21. She Q-B, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/ MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005 Oct;8(4):287-297.
22. Scheid MP, Schubert KM, Duronio V. Regulation of Bad Phosphorylation and Association with Bcl-xL by the MAPK/Erk Kinase. Journal of Biological Chemistry 1999 Oct;274(43):31108 -31113.
23. Eads D, Hansen R, Oyegunwa A, Cecil C, Culver C, Scholle F, Petty I, Laster S. Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines. Journal of Inflammation 2009;6:2
24. Youngren J, Gable K, Penaranda C, Maddux B, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine I. Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells. Breast Cancer Research and Treatment 2005 Nov;94(1):37-46.
25. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings of the National Academy of Sciences 1998 Mar;95(6):3003-3007.
26. Dokmanovic M, Clarke C, Marks PA. Histone Deacetylase Inhibitors: Overview and Perspectives. Molecular Cancer Research 2007 Oct;5(10):981 -989.
27. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji Q-S. Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Research 2008 Oct;68(20):8322-8332.
28. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME. 14-3-3 Proteins and Survival Kinases Cooperate to Inactivate BAD by BH3 Domain Phosphorylation. Molecular Cell 2000 Jul;6(1):41-51.
29. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS One 2009 Nov;4(11):e7887
30. Bliss C. The toxicity of poisons applied jointly. Annals of Applied Biology 1939;(26):585-615.
31. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2(9):458-466.
32. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D. CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation. Molecular Endocrinology 2010 Dec;24(12):2267 -2280.
33. Montgomery DC. Design and Analysis of Experiments. 7th ed. New York: John Wiley & Sons; 2009.